Drugs / Human recombinant hyaluronidase
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00740727 Background | Feb → Mar 2009 | — | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human recombinant hyaluronidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00740727 ↗ |
| Known as | HRH | “Human recombinant hyaluronidase (HRH) as part of the EASI placement.” NCT00740727 ↗ |
| Modality | Protein / enzyme biologic | “Enzyme-assisted subcutaneous infusion (EASI) access, in which human recombinant hyaluronidase (HRH) augments subcutaneous fluid dispersion and absorption” PMID 22854002 ↗ Jun 2012 |